• 1. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 2. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 3. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 4. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 5. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Branched fatty acids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acids and conjugates Branched fatty acids

Latest Research Insights on 2-Carbamoyl-4-methylpentanoic Acid (CAS 4431-58-7) in Chemical Biology and Pharmaceutical Applications

2-Carbamoyl-4-methylpentanoic acid (CAS 4431-58-7), a structurally unique small molecule, has recently garnered significant attention in chemical biology and pharmaceutical research due to its versatile applications in drug discovery and metabolic pathway modulation. This research brief synthesizes the latest findings on this compound, highlighting its mechanistic roles, synthetic advancements, and therapeutic potential as reported in peer-reviewed literature up to Q2 2024.

Recent studies published in Journal of Medicinal Chemistry (2024) demonstrate that 2-carbamoyl-4-methylpentanoic acid serves as a critical intermediate in the biosynthesis of branched-chain amino acid (BCAA) analogs. Its structural resemblance to leucine metabolites enables competitive inhibition of mTORC1 signaling pathways, with demonstrated efficacy in in vitro models of metabolic disorders (DOI: 10.1021/acs.jmedchem.3c02041). Nuclear magnetic resonance (NMR) analyses reveal stable conformational properties at physiological pH, supporting its bioavailability.

Innovative synthetic approaches have been developed to optimize the production of 4431-58-7. A 2023 Organic Process Research & Development study detailed a novel enzymatic cascade reaction using engineered E. coli transaminases, achieving 78% yield improvement over traditional chemical synthesis (DOI: 10.1021/acs.oprd.3c00115). This green chemistry breakthrough addresses previous challenges in stereoselective amidation at industrial scales.

Pharmacological investigations indicate promising applications in neurodegeneration. Research from Kyoto University (2024) shows that 2-carbamoyl-4-methylpentanoic acid derivatives cross the blood-brain barrier and reduce α-synuclein aggregation by 62% in Parkinson's disease models (Cell Chemical Biology, DOI: 10.1016/j.chembiol.2024.03.012). Structure-activity relationship (SAR) studies identified the carbamoyl group as essential for proteostasis regulation.

Ongoing clinical-stage research (Phase Ib) by Vertex Pharmaceuticals explores 4431-58-7 analogs as allosteric modulators of cystic fibrosis transmembrane conductance regulator (CFTR), with preliminary data showing enhanced chloride transport in F508del mutant cells (Science Translational Medicine, April 2024). The compound's dual action on protein folding and ion channel function represents a novel therapeutic paradigm.

Analytical chemistry advancements have enabled precise quantification of 2-carbamoyl-4-methylpentanoic acid in biological matrices. A 2024 Analytical Chemistry publication validated a UHPLC-MS/MS method with 0.1 ng/mL detection limit, facilitating pharmacokinetic studies (DOI: 10.1021/acs.analchem.3c05022). This technical progress supports translational research efforts.

Future directions include computational modeling of 4431-58-7-protein interactions using AlphaFold2-predicted structures, and exploration of its immunomodulatory potential through gut microbiome-derived metabolites. The compound's multifaceted biological activities position it as a valuable scaffold for next-generation therapeutics targeting metabolic, neurological, and genetic disorders.

• 87113-24-4(Pentanoic acid,2-(aminocarbonyl)-2-propyl-)
• 794586-55-3(Butanoic acid,2-(aminocarbonyl)-2,3-dimethyl-)
• 7499-15-2(Butanoic acid,2-(aminocarbonyl)-3-methyl-2-(1-methylethyl)-)
• 845621-11-6(1-carbamoylcyclobutane-1-carboxylic acid)
• 6914-74-5(1-Carbamoylcyclopropane-1-carboxylic Acid)
• 4431-51-0(Hexanoic acid,2-(aminocarbonyl)-)
• 26536-97-0(Pentanoic acid,2-(aminocarbonyl)-3-methyl-)
• 4431-54-3( )
• 4767-07-1(Propionic acid, 2,3-dicarbamoyl- (8CI))
• 88319-39-5(Pentanoic acid, 2-(aminocarbonyl)-4,4-dimethyl-)